A recent cross-sectional analysis from the SpA-Net registry highlights that nearly one in ten individuals with axial spondyloarthritis (axSpA) face challenges in disease management. The study, published in Rheumatology, assesses the prevalence and underlying factors contributing to difficult-to-manage axSpA (D2M axSpA) based on the Assessment of SpondyloArthritis international Society (ASAS) criteria.
Prevalence and Contributing Factors Identified
Analyzing data from 263 patients, researchers found that 9.7% met the criteria for D2M axSpA. Specifically, variations in the ASAS definition revealed that treatment failure affected up to 11.6% of patients, while insufficient disease control was observed in approximately 79.7%. Among these, high disease activity, active disease signs, and reduced quality of life were significant contributors. Additionally, problematic management situations were reported in over half of the cases.
Associated Patient Characteristics
The study identified current smoking and a history of psoriasis as notable characteristics associated with D2M axSpA. Smokers were found to have a threefold increase in the likelihood of experiencing difficult-to-manage disease, while individuals with psoriasis had nearly three times the odds compared to those without these factors.
Inferences drawn from the study include:
- High disease activity and active disease signs are primary drivers of inadequate disease control in axSpA patients.
- Smoking cessation and psoriasis management could potentially mitigate the challenges in managing axSpA.
- Patient-reported outcomes play a crucial role in classifying and understanding D2M axSpA.
Effective management strategies for axSpA must consider both clinical indicators and patient-reported experiences to address the complex nature of D2M axSpA. Integrating comprehensive patient assessments can lead to more personalized treatment plans, potentially reducing the burden of disease and improving quality of life for affected individuals.
The findings underscore the importance of holistic approaches in rheumatological care, emphasizing the need for clinicians to address lifestyle factors such as smoking and comorbid conditions like psoriasis. By targeting these associated characteristics, healthcare providers can enhance disease management and outcomes for patients with axSpA.
Advanced screening and tailored interventions based on patient profiles may offer pathways to better control of axSpA, particularly for those classified under D2M axSpA. Future research should explore the efficacy of integrated care models that incorporate both medical and psychosocial support to tackle the multifaceted challenges presented by this condition.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
